以岭药业芪防鼻通片进入国家医保，以研发创新驱动中医药高质量发展

Core Viewpoint - Yiling Pharmaceutical's product Qifang Nizhong Pian has been included in the national medical insurance directory, marking a significant milestone for the company and the innovation of traditional Chinese medicine [1][3]. Group 1: Product and Innovation - Qifang Nizhong Pian is the first innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, filling a clinical gap [1][3]. - The product received approval from the National Medical Products Administration in January 2025 and was launched in Macau in July 2025, becoming the first innovative traditional Chinese medicine registered in Macau [3]. - The inclusion in the medical insurance directory is a recognition of the product's innovation, clinical efficacy, and safety, which will significantly enhance its accessibility and affordability [3]. Group 2: R&D Investment and Achievements - Yiling Pharmaceutical has maintained a high level of R&D investment, with R&D expenses reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of revenue [4]. - From 2019 to 2024, the company’s cumulative R&D investment exceeded 5 billion yuan, consistently leading the industry average [4]. - The company has developed 17 patented traditional Chinese medicines covering eight major clinical disease systems, with 12 products included in the national medical insurance directory and 5 in the national essential drug list [4]. Group 3: Future Prospects and Team Structure - Yiling Pharmaceutical has a robust pipeline of products, with several traditional Chinese medicines and chemical drugs at various stages of clinical research and application [5]. - The company has established a high-quality research and management team, recognized as part of Hebei Province's "Giant Plan" and awarded multiple national and provincial scientific achievement awards [5]. - The company’s commitment to innovation and quality control positions it as a benchmark enterprise in the pharmaceutical industry, driving the development of traditional Chinese medicine [6].